Moelis Adds Ex-Teva CEO Yanai for Health-Care, Technology Deals

  • Yanai is director at biotech firm Protalix, drugmaker Perrigo
  • Moelis will seek more bankers in health care and technology

Moelis & Co., the investment bank founded by Wall Street veteran Ken Moelis, said Shlomo Yanai, the former chief executive officer of Teva Pharmaceutical Industries Ltd., has joined as a senior adviser.

“His deep relationships with multinational companies in the health-care, industrials, technology, and business-services sectors will provide exceptional benefit to our clients across,” Ken Moelis said Monday in a statement on the New York-based company’s website.

The firm plans to add dealmakers for health care, in anticipation of mergers and acquisitions in the industry, Vice Chairman Rick Leaman said in a September presentation to investors. A former Israeli Army general, Yanai led Teva, the world’s largest maker of generic drugs, for about five years, stepping down in 2012. He is chairman of Protalix BioTherapeutics Inc. and a director at drugmaker Perrigo Co.

“As a corporate executive, particularly when executing M&A, I have recognized the value of independent advice and the trust that results from long-term relationships,” Yanai said in the statement.

Yanai had no pharmaceutical industry experience before joining Teva. While at the drugmaker, he shepherded transactions including the takeover of Cephalon Inc. for more than $6 billion, winning the deal over a hostile offer from Valeant Pharmaceuticals International Inc. He also beat competitors who sought to acquire Ratiopharm GmbH, agreeing in 2010 to buy the firm for almost $5 billion.

    Before it's here, it's on the Bloomberg Terminal.